Recently, Shenzhen CAS MicroLight Medical Instruments Co., Ltd. proudly announced the successful completion of a financing round amounting to hundreds of millions of yuan. This significant funding round was spearheaded by Sino-US Green Yangtze River Delta and Yifeng Capital, with Bank of China Capital and Huiyu Investment joining as key participants. The influx of capital will be predominantly allocated towards the global commercialization of the company's core products. Additionally, it will fuel the research and development efforts, facilitate registration processes, and drive clinical advancements for its innovative pipeline projects. This strategic move is set to further cement MicroLight Medical's robust position within the realm of intelligent intervention.

Leveraging cutting-edge laser and multi-energy platform technologies, MicroLight Medical has honed its focus on addressing complex coronary and peripheral vascular diseases. The company is at the forefront of constructing an AI-driven, integrated intelligent intervention solution that encompasses diagnosis, treatment, and assessment. With a vision to emerge as a globally competitive platform enterprise in the field of complex pan-vascular diseases, MicroLight Medical is poised to make significant strides in revolutionizing healthcare solutions.